(Q28074769)

Carol A. Brenner

series ordinal

2

1 reference

Meenakshi Singh

series ordinal

3

1 reference

language of work or name

1 reference

January 2016

1 reference

American Journal of Clinical Pathology

published in

1 reference

volume

145

1 reference

issue

1

1 reference

page(s)

8-21

1 reference

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Type I and II endometrial cancers: have they different risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Resistance to chemotherapy and hormone therapy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Factors associated with Type I and Type II endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Histopathology of endometrial hyperplasia and endometrial carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

21 January 2018

Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

High-grade endometrial carcinomas - strategies for typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Prognostic features of surgical stage I uterine carcinosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Endometrial carcinoma: molecular alterations involved in tumor development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Molecular pathology of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Novel molecular profiles of endometrial cancer-new light through old windows.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Molecular carcinogenesis of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

The role of para-aortic lymphadenectomy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Treatment options for advanced endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Histopathologic variables predict Oncotype DX recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Progesterone: the ultimate endometrial tumor suppressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Progestin intrauterine device in an adolescent with grade 2 endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Personalized therapy in endometrial cancer: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Biochemical and structural analysis of alpha-catenin in cell-cell contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Oncogenic roles of EMT-inducing transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

The role of the EGFR signaling in tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQV014